Skip to content

Avalo Therapeutics AVTX Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-88.8%-72.4%-22.4pp-177.4%-133pp
Liquidity
Current ratio7.7×-14.9×8.1×-11.8×14.3×+12.9×12.4×+11.4×22.6×+22.1×
Leverage
Debt-to-equity0.0×0.0×-0.1×
Per Share
Book value per share$3.40-70.9%$6.20-65.1%$6.54+235%$9.66+643%$11.66+109%
Valuation
Market capitalization$954.59M+1,800%$329.31M+324%$167.17M+81.4%$53.6M+316%$85.48M+390%
Price / book14×+13.6×+3.4×1.8×-2.5×0.5×0.7×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Avalo Therapeutics's profit margins?
Avalo Therapeutics (AVTX) runs a 182.0% gross margin and a -15536.1% operating margin, with a -7965.8% net margin.
Where do Avalo Therapeutics's ratios come from?
Every ratio is computed from Avalo Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.